Company Filing History:
1 out of 989 
1 out of 21 
1 out of 134 
Years Active: 2024
Title: The Innovative Contributions of Shinji Matsumoto
Introduction
Shinji Matsumoto is a notable inventor based in Suita, Japan. He has made significant contributions to the field of biomedical innovation, particularly in the development of nucleic acid drugs. His work focuses on targeting specific molecules to exert therapeutic effects, showcasing the potential of antisense oligonucleotides in cancer treatment.
Latest Patents
Matsumoto holds a patent for an "Antisense oligonucleotide targeting ARL4C molecule, and nucleic acid drug using antisense oligonucleotide." The purpose of this invention is to provide an antisense oligonucleotide that targets the ARL4C molecule, which has been shown to exert an antitumor effect in vivo. This antisense oligonucleotide consists of a base sequence with at least 10 consecutive bases from the sequence represented by SEQ ID NO: 1. It effectively inhibits the expression of ARL4C in tumor cells in vitro, suppressing their migration and proliferation. Furthermore, when administered systemically, this oligonucleotide demonstrates an excellent antitumor effect in vivo.
Career Highlights
Throughout his career, Shinji Matsumoto has worked with prestigious institutions, including Osaka University and the National Institutes of Biomedical Innovation, Health and Nutrition. His research has contributed to advancements in the understanding and treatment of cancer, particularly through the use of innovative nucleic acid technologies.
Collaborations
Matsumoto has collaborated with esteemed colleagues such as Akira Kikuchi and Satoshi Obika. These partnerships have fostered a collaborative environment that enhances the research and development of groundbreaking biomedical solutions.
Conclusion
Shinji Matsumoto's work exemplifies the impact of innovative research in the field of medicine. His contributions to the development of antisense oligonucleotides highlight the potential for targeted therapies in cancer treatment. His ongoing efforts continue to inspire advancements in biomedical innovation.